MA51615A - Polytherapie pour le traitement ou la prévention du cancer - Google Patents

Polytherapie pour le traitement ou la prévention du cancer

Info

Publication number
MA51615A
MA51615A MA051615A MA51615A MA51615A MA 51615 A MA51615 A MA 51615A MA 051615 A MA051615 A MA 051615A MA 51615 A MA51615 A MA 51615A MA 51615 A MA51615 A MA 51615A
Authority
MA
Morocco
Prior art keywords
polytherapy
cancer
prevention
treatment
Prior art date
Application number
MA051615A
Other languages
English (en)
Inventor
Alexander Stevenson
Original Assignee
4D Pharma Res Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1800927.4A external-priority patent/GB201800927D0/en
Priority claimed from GBGB1801502.4A external-priority patent/GB201801502D0/en
Priority claimed from GBGB1805941.0A external-priority patent/GB201805941D0/en
Priority claimed from GBGB1806572.2A external-priority patent/GB201806572D0/en
Priority claimed from GBGB1808631.4A external-priority patent/GB201808631D0/en
Application filed by 4D Pharma Res Ltd filed Critical 4D Pharma Res Ltd
Publication of MA51615A publication Critical patent/MA51615A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C07K16/3084—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated gangliosides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
MA051615A 2018-01-19 2019-01-18 Polytherapie pour le traitement ou la prévention du cancer MA51615A (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB1800927.4A GB201800927D0 (en) 2018-01-19 2018-01-19 Combination therapy for treating or preventing cancer
GBGB1801502.4A GB201801502D0 (en) 2018-01-30 2018-01-30 Combination therapy for treating or preventing cancer
GBGB1805941.0A GB201805941D0 (en) 2018-04-10 2018-04-10 Combination therapy for treating or preventing cancer
GBGB1806572.2A GB201806572D0 (en) 2018-04-23 2018-04-23 Combination therapy for treating or preventing cancer
GBGB1808631.4A GB201808631D0 (en) 2018-05-25 2018-05-25 Combination therapy for treating or preventing cancer

Publications (1)

Publication Number Publication Date
MA51615A true MA51615A (fr) 2020-11-25

Family

ID=65278398

Family Applications (1)

Application Number Title Priority Date Filing Date
MA051615A MA51615A (fr) 2018-01-19 2019-01-18 Polytherapie pour le traitement ou la prévention du cancer

Country Status (14)

Country Link
US (2) US20210060086A1 (fr)
EP (1) EP3740220A1 (fr)
JP (1) JP2021516662A (fr)
KR (1) KR20200110342A (fr)
CN (1) CN111727047A (fr)
AU (1) AU2019210004A1 (fr)
BR (1) BR112020014565A2 (fr)
CA (1) CA3088338A1 (fr)
IL (1) IL276074A (fr)
MA (1) MA51615A (fr)
MX (1) MX2020007664A (fr)
SG (1) SG11202006873UA (fr)
TW (1) TW201934139A (fr)
WO (1) WO2019141998A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020324185A1 (en) * 2019-08-02 2022-03-03 CTTQ-Akeso (ShangHai) Biomed. Tech. Co., Ltd. Anti-PD-1 antibody and medical use thereof
EP4056200A4 (fr) * 2019-11-04 2024-01-10 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Association de médicaments d'un dérivé de quinoléine et d'un anticorps monoclonal pd -1
CN117425671A (zh) * 2021-03-25 2024-01-19 T3制药股份公司 用于治疗癌症的药物组合
WO2023072968A1 (fr) * 2021-10-25 2023-05-04 4D Pharma Research Ltd Compositions comprenant des souches bactériennes

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0127916D0 (en) 2001-11-21 2002-01-16 Rowett Res Inst Method
EP3954715A3 (fr) 2006-10-27 2022-05-04 Capsugel Belgium NV Capsules dures en hydroxypropylméthylcellulose et leur procédé de fabrication
GB201112091D0 (en) 2011-07-14 2011-08-31 Gt Biolog Ltd Bacterial strains isolated from pigs
GB201117313D0 (en) 2011-10-07 2011-11-16 Gt Biolog Ltd Bacterium for use in medicine
GB201306536D0 (en) 2013-04-10 2013-05-22 Gt Biolog Ltd Polypeptide and immune modulation
AU2016270750B2 (en) * 2015-06-01 2022-06-16 The University Of Chicago Treatment of cancer by manipulation of commensal microflora
HRP20180501T1 (hr) 2015-11-20 2018-06-01 4D Pharma Research Limited Pripravci koje sadrže bakterijske sojeve
GB201520497D0 (en) * 2015-11-20 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
MA41708A (fr) * 2017-05-24 2020-04-08 4D Pharma Res Ltd Compositions comprenant des souches bactériennes

Also Published As

Publication number Publication date
MX2020007664A (es) 2020-09-14
KR20200110342A (ko) 2020-09-23
US20210060086A1 (en) 2021-03-04
BR112020014565A2 (pt) 2020-12-08
JP2021516662A (ja) 2021-07-08
EP3740220A1 (fr) 2020-11-25
IL276074A (en) 2020-08-31
SG11202006873UA (en) 2020-08-28
CA3088338A1 (fr) 2019-07-25
CN111727047A (zh) 2020-09-29
TW201934139A (zh) 2019-09-01
AU2019210004A1 (en) 2020-08-13
US20230277602A1 (en) 2023-09-07
WO2019141998A1 (fr) 2019-07-25

Similar Documents

Publication Publication Date Title
EP3893940A4 (fr) Polythérapie pour le traitement de la dystrophie musculaire
MA49144A (fr) Polythérapies pour le traitement du cancer
EP3600281A4 (fr) Traitement d'association pour le traitement ou la prévention de tumeurs
EP3452060A4 (fr) Polythérapie pour le traitement du cancer
MA56508A (fr) Inhibiteur d'egfr pour le traitement du cancer
EP3431105A4 (fr) Composition médicinale pour le traitement du cancer
EP3570844A4 (fr) Azolopyrimidine pour le traitement de troubles liés au cancer
MA50409A (fr) Polythérapies pour le traitement du cancer
EP3641829A4 (fr) Promédicament d'interféron pour le traitement du cancer
MA48637A (fr) Polythérapies pour le traitement du cancer
EP3533466A4 (fr) Composition pharmaceutique pour le traitement et/ou la prévention du cancer
MA43000A (fr) Polythérapie pour le traitement de tumeurs malignes
EP3362065A4 (fr) Polythérapie pour le traitement de malignités
EP3541417A4 (fr) Immunothérapies d'association pour le traitement du cancer
EP3766497A4 (fr) Médicament pour le traitement de la toux
MA51613A (fr) Polythérapie pour le traitement ou la prévention du cancer
EP3490561A4 (fr) Combinaisons pour le traitement du cancer
MA55218A (fr) Eskétamine pour le traitement de la dépression
EP3443962A4 (fr) Dérivé de quinoline pour le traitement du cancer de l'estomac
EP3773221A4 (fr) Traitement pour l'hydrocéphalie
EP3630080A4 (fr) Utilisation d'inhibiteurs de ezh2 pour le traitement du cancer
EP3793544A4 (fr) Compositions bifonctionnelles pour le traitement du cancer
EP3471722A4 (fr) Composés et méthodes pour la prévention et/ou le traitement du cancer
EP3503887A4 (fr) Combinaisons pour le traitement du cancer
MA51615A (fr) Polytherapie pour le traitement ou la prévention du cancer